PURPOSE: We assessed the usefulness of real-time molecular profiling through next-generation sequencing (NGS) in predicting the tumor biology of advanced pancreatic neuroendocrine tumors (panNETs) and in characterizing genomic evolution. METHODS: Patients with metastatic panNETs were recruited in the routine clinical practice setting (between May 2014 and March 2017) for prospective NGS of their tumors as well as for germline analysis using the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) sequencing platform. When possible, NGS was performed at multiple time points. RESULTS: NGS was performed in 96 tumor samples from 80 patients. Somatic alterations were identified in 76 of 80 patients (95%). The most commonly altered genes were MEN1 (56%), DAXX (40%), ATRX (25%), and TSC2 (25%). Alterations could be defined in pathways that included chromatin remodeling factors, histone methyltransferases, and mammalian target of rapamycin pathway genes. Somatic loss of heterozygosity was particularly prevalent (50 of 96 samples [52%]), and the presence of loss of heterozygosity resulted in inferior overall survival (P < .01). Sequencing of pre- and post-treatment samples revealed tumor-grade progression; clonal evolution patterns were also seen (molecular resistance mechanisms and chemotherapy-associated mutagenesis). Germline genetic analysis identified clinically actionable pathogenic or likely pathogenic variants in 14 of 88 patients (16%), including mutations in high-penetrance cancer susceptibility genes (MEN1, TSC2, and VHL). CONCLUSION: A clinical NGS platform reveals pertubations of biologic pathways in metastatic panNETs that may inform prognosis and direct therapies. Repeat sequencing at disease progression reveals increasing tumor grade and genetic evolution, demonstrating that panNETs adopt a more aggressive behavior through time and therapies. In addition to frequent somatic mutations in MEN1 and TSC2, germline mutations in these same genes underlie susceptibility to panNETs and highlight the need to re-evaluate whether germline genetic analysis should be performed for all patients with panNETs.
PURPOSE: We assessed the usefulness of real-time molecular profiling through next-generation sequencing (NGS) in predicting the tumor biology of advanced pancreatic neuroendocrine tumors (panNETs) and in characterizing genomic evolution. METHODS: Patients with metastatic panNETs were recruited in the routine clinical practice setting (between May 2014 and March 2017) for prospective NGS of their tumors as well as for germline analysis using the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) sequencing platform. When possible, NGS was performed at multiple time points. RESULTS: NGS was performed in 96 tumor samples from 80 patients. Somatic alterations were identified in 76 of 80 patients (95%). The most commonly altered genes were MEN1 (56%), DAXX (40%), ATRX (25%), and TSC2 (25%). Alterations could be defined in pathways that included chromatin remodeling factors, histone methyltransferases, and mammalian target of rapamycin pathway genes. Somatic loss of heterozygosity was particularly prevalent (50 of 96 samples [52%]), and the presence of loss of heterozygosity resulted in inferior overall survival (P < .01). Sequencing of pre- and post-treatment samples revealed tumor-grade progression; clonal evolution patterns were also seen (molecular resistance mechanisms and chemotherapy-associated mutagenesis). Germline genetic analysis identified clinically actionable pathogenic or likely pathogenic variants in 14 of 88 patients (16%), including mutations in high-penetrance cancer susceptibility genes (MEN1, TSC2, and VHL). CONCLUSION: A clinical NGS platform reveals pertubations of biologic pathways in metastatic panNETs that may inform prognosis and direct therapies. Repeat sequencing at disease progression reveals increasing tumor grade and genetic evolution, demonstrating that panNETs adopt a more aggressive behavior through time and therapies. In addition to frequent somatic mutations in MEN1 and TSC2, germline mutations in these same genes underlie susceptibility to panNETs and highlight the need to re-evaluate whether germline genetic analysis should be performed for all patients with panNETs.
Authors: Yuchen Jiao; Chanjuan Shi; Barish H Edil; Roeland F de Wilde; David S Klimstra; Anirban Maitra; Richard D Schulick; Laura H Tang; Christopher L Wolfgang; Michael A Choti; Victor E Velculescu; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos Journal: Science Date: 2011-01-20 Impact factor: 47.728
Authors: Jonathan R Strosberg; Robert L Fine; Junsung Choi; Aejaz Nasir; Domenico Coppola; Dung-Tsa Chen; James Helm; Larry Kvols Journal: Cancer Date: 2010-09-07 Impact factor: 6.860
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: James C Yao; Catherine Lombard-Bohas; Eric Baudin; Larry K Kvols; Philippe Rougier; Philippe Ruszniewski; Sakina Hoosen; Jessica St Peter; Tomas Haas; David Lebwohl; Eric Van Cutsem; Matthew H Kulke; Timothy J Hobday; Thomas M O'Dorisio; Manisha H Shah; Guillaume Cadiot; Gabriele Luppi; James A Posey; Bertram Wiedenmann Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544
Authors: Matthew H Kulke; Heinz-Josef Lenz; Neal J Meropol; James Posey; David P Ryan; Joel Picus; Emily Bergsland; Keith Stuart; Lesley Tye; Xin Huang; Jim Z Li; Charles M Baum; Charles S Fuchs Journal: J Clin Oncol Date: 2008-07-10 Impact factor: 44.544
Authors: James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam Journal: J Clin Oncol Date: 2008-09-10 Impact factor: 44.544
Authors: Andreas Gnirke; Alexandre Melnikov; Jared Maguire; Peter Rogov; Emily M LeProust; William Brockman; Timothy Fennell; Georgia Giannoukos; Sheila Fisher; Carsten Russ; Stacey Gabriel; David B Jaffe; Eric S Lander; Chad Nusbaum Journal: Nat Biotechnol Date: 2009-02-01 Impact factor: 54.908
Authors: Chandra K Maharjan; Po Hien Ear; Catherine G Tran; James R Howe; Chandrikha Chandrasekharan; Dawn E Quelle Journal: Cancers (Basel) Date: 2021-10-12 Impact factor: 6.639
Authors: Fangdi Sun; James P Grenert; Lisa Tan; Jessica Van Ziffle; Nancy M Joseph; Claire K Mulvey; Emily Bergsland Journal: JCO Precis Oncol Date: 2022-06
Authors: K G Samsom; L M van Veenendaal; G D Valk; M R Vriens; M E T Tesselaar; J G van den Berg Journal: Endocr Connect Date: 2019-07 Impact factor: 3.335
Authors: Alberto Puccini; Kelsey Poorman; Mohamed E Salem; Davide Soldato; Andreas Seeber; Richard M Goldberg; Anthony F Shields; Joanne Xiu; Francesca Battaglin; Martin D Berger; Ryuma Tokunaga; Madiha Naseem; Afsaneh Barzi; Syma Iqbal; Wu Zhang; Shivani Soni; Jimmy J Hwang; Philip A Philip; Stefania Sciallero; W Michael Korn; John L Marshall; Heinz-Josef Lenz Journal: Clin Cancer Res Date: 2020-09-03 Impact factor: 12.531
Authors: Alessandra Pulvirenti; Nitya Raj; Sara Cingarlini; Antonio Pea; Laura H Tang; Claudio Luchini; Joanne F Chou; Elisabetta Grego; Ioana Marinova; Marinela Capanu; Luca Landoni; Aldo Scarpa; Peter J Allen; David S Klimstra; Diane L Reidy-Lagunes Journal: Pancreas Date: 2021-02-01 Impact factor: 3.243